Senate Compounding Bill Clears Senate Committee

Published Online: Tuesday, June 18, 2013
Follow Pharmacy_Times:
On May 22, 2013, a US Senate committee passed a bipartisan bill that would increase regulation of compounding pharmacies that produce sterile drugs without a prescription and ship them across state lines. The bill, which is expected to be considered by the full Senate in June or July, was developed in response to last fall’s fungal meningitis outbreak caused by contaminated steroids produced by a Massachusetts compounding pharmacy. The outbreak killed 55 and sickened almost 750.

The bill would require “compounding manufacturers” to report adverse events associated with compounded drugs, would give the FDA clear authority to inspect compounders, and would require that compounded drugs be clearly labeled as such. Compounders that only ship within state lines and hospital pharmacies—even those that distribute sterile products to out-of-state hospitals within their system—would continue to be overseen by state boards of pharmacy. The bill would not ban the compounding of any drug, but would allow the FDA to keep a list of drugs that should not be compounded due to safety concerns.

The US Senate Health, Education, Labor, and Pensions Committee also issued a report finding that problems with compounding have continued in the months since the fungal meningitis outbreak. It found that at least 48 compounders produced drugs that were contaminated, were produced in unsafe conditions, or were otherwise in violation of laws. In addition, the report noted that 11 compounders have been ordered by state boards of pharmacy to stop producing some or all drugs and 10 have issued national recalls due to concerns over contamination.

Related Articles
The $200 million fund created to compensate victims of the 2012 meningitis outbreak tied to tainted drugs is an extreme example of how expensive compounding errors can be.
Lipscomb University College of Pharmacy students recently began working in a new sterile compounding laboratory constructed partly in response to the fungal meningitis outbreak in 2012.
Compounding pharmacies across the nation face tighter regulations following the 2012 fungal meningitis outbreak from tainted drugs distributed by the New England Compounding Center.
Lisa Faast, PharmD, pharmacy business specialist and member of Pharmacy Development Services, talks about how pharmacists' awareness of sterile compounding procedures has changed since the 2012 meningitis outbreak.
Latest Issues